Healthcare and Lifesciences
VedaCorp advises Iswarya Fertility Center, India’s leading and fast-growing IVF chain, on its growth investment of INR 350+ crore from OrbiMed Asia
About
Iswarya Fertility
Established in 1986 by Dr. S. Chandralekha and Dr. Veluswamy, Iswarya Fertility Center is one of India’s leading fertility care providers with a network of 81 centres across eight states. Iswarya combines clinical excellence, advanced technology and compassionate care to make parenthood possible for families across India.
OrbiMed Asia
OrbiMed Asia is a leading global healthcare investment firm with a dedicated focus on investing across the healthcare sector, including biopharmaceuticals, medical devices, diagnostics, healthcare services and healthcare technology. With decades of experience and offices across major global markets, OrbiMed partners with innovative healthcare companies to support their long-term growth and value creation.
Background
We are pleased to announce that our client, Iswarya Fertility Center (“Iswarya”), has secured a growth investment of over INR 350 crore (approximately US$37 million) from OrbiMed Asia (“OrbiMed”), a leading global healthcare investment firm. The capital will fuel Iswarya’s expansion into new and underserved markets, strengthen its clinical infrastructure, accelerate digital capabilities and grow its embryology talent pipeline.
Established in 1986, Iswarya has evolved into India’s leading and fast growing fertility network with 80+ centres across eight states, serving more than 300,000 couples over four decades. Led by Managing Director Dr. Arun Muthuvel, the company offers services spanning IVF, IUI, fertility preservation, genetics and advanced reproductive treatments.
Veda Corporate Advisors (“VedaCorp”) acted as exclusive financial advisor to Iswarya and its promoters. VedaCorp provided comprehensive transaction advisory services covering identification of prospective investors, strategic positioning, deal structuring and negotiation of key commercial terms through to the successful closure.
VedaCorp operates across multi-specialty, single-specialty, diagnostics, pharma, and medtech, giving us deep, cross-cutting insight into India’s healthcare landscape.
This transaction marks VedaCorp’s 6th transaction in the single-specialty space in the last 12 months, its 23rd transaction in the single-specialty segment overall, and 65th deal in healthcare and life sciences — reinforcing our position as a market leader & a trusted advisor to founders and investors in specialised, high-growth healthcare businesses.
“VedaCorp was instrumental in helping us close our INR 350 crore Series A round. Their deep understanding of the fertility and healthcare space, coupled with strong investor relationships and hands-on execution, meant we had the right investors at the table quickly and on strong terms. They managed a complex process with precision while letting our team stay focused on the business. We couldn’t have asked for a better banking partner for this milestone”
Dr. Arun Muthuvel, Managing Director
Iswarya Fertility Center
“Iswarya represents a rare combination of clinical depth, brand trust and disciplined execution. The transaction drew strong interest from marquee investors, and we are delighted to have advised the promoters on this landmark deal for India’s fertility sector”
V P Rajan
Managing Director – VedaCorp